E-LIB Suche - Ergebnisse für: Maddocks, Kami

1

Siltuximab Prophylaxis Prior to Standard of Care CD19 Direc..:

Voorhees, Timothy ; Huang, Ying ; Denlinger, Nathan...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S355-S356 , 2024

Link: https://doi.org/10.1016/..

2

Acalabrutinib plus venetoclax and rituximab in treatment-na..:

Wang, Michael L ; Robak Prof., Tadeusz ; Maddocks, Kami J...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

3

Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refracto..:

Mei, Matthew ; Tsai, Ni-Chun ; Palmer, Joycelynne...
Clinical Lymphoma Myeloma and Leukemia. , 2024

Link: https://doi.org/10.1016/..

4

Postinfusion PD-1+ CD8+ CAR T cells identify patients respo..:

Denlinger, Nathan ; Song, No-Joon ; Zhang, Xiaoli...
Blood Advances. 8 (2024) 12 - p. 3140-3153 , 2024

Link: https://doi.org/10.1182/..

5

Safety of extended pirtobrutinib exposure in relapsed and/o..:

Roeker, Lindsey E. ; Coombs, Catherine C. ; Shah, Nirav N....
Acta Haematologica. , 2024

Link: https://doi.org/10.1159/..

6

Prognostic relevance of circulating lymphoma cells at diagn..:

Annunzio, Kaitlin ; Bhatta, Subodh ; Hanel, Walter...
Hematological Oncology. 42 (2024) 3 - p. , 2024

Link: https://doi.org/10.1002/..

7

Does TRIANGLE take down transplantation in mantle cell lymp..:

Martin, Peter ; Maddocks, Kami
The Lancet. 403 (2024) 10441 - p. 2264-2265 , 2024

Link: https://doi.org/10.1016/..

8

Development of recalcitrant cutaneous eruptions in patients..:

Himed, Sonia ; Chung, Catherine ; Dulmage, Brittany...
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 7 - p. , 2023

Link: https://doi.org/10.1111/..

9

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALI..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
HemaSphere. 7 (2023) S3 - p. e7389505 , 2023

Link: https://doi.org/10.1097/..

10

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATI..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
HemaSphere. 7 (2023) S3 - p. e4580941 , 2023

Link: https://doi.org/10.1097/..

11

CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in..:

Muehlenbein, Catherine E. ; Coombs, Catherine C. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S520 , 2023

Link: https://doi.org/10.1016/..

12

P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY..:

Bond, David ; Yildiz, Vedat ; Wei, Lai...
HemaSphere. 7 (2023) S3 - p. e1419630 , 2023

Link: https://doi.org/10.1097/..

13

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED ..:

Jurczak, Wojciech ; Luigi Zinzani, Pier ; Eyre, Toby A....
HemaSphere. 7 (2023) S3 - p. e45636b5 , 2023

Link: https://doi.org/10.1097/..

14

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Pa..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S433-S434 , 2023

Link: https://doi.org/10.1016/..

15

Adding venetoclax to lenalidomide and rituximab is safe and..:

Phillips, Tycel J. ; Bond, David ; Takiar, Radihka...
Blood Advances. 7 (2023) 16 - p. 4518-4527 , 2023

Link: https://doi.org/10.1182/..